| Targeted alpha therapy using short-lived alpha-particles and the promise of nanobodies as targeting vehicle Y Dekempeneer, M Keyaerts, A Krasniqi, J Puttemans, S Muyldermans, ... Expert opinion on biological therapy 16 (8), 1035-1047, 2016 | 155 | 2016 |
| Labeling of anti-HER2 nanobodies with astatine-211: optimization and the effect of different coupling reagents on their in vivo behavior Y Dekempeneer, T Bäck, E Aneheim, H Jensen, J Puttemans, C Xavier, ... Molecular Pharmaceutics 16 (8), 3524-3533, 2019 | 51 | 2019 |
| Preclinical Targeted α- and β−-Radionuclide Therapy in HER2-Positive Brain Metastasis Using Camelid Single-Domain Antibodies J Puttemans, Y Dekempeneer, JL Eersels, H Hanssens, P Debie, ... Cancers 12 (4), 1017, 2020 | 48 | 2020 |
| Therapeutic Efficacy of 213Bi-labeled sdAbs in a Preclinical Model of Ovarian Cancer Y Dekempeneer, V Caveliers, M Ooms, D Maertens, M Gysemans, ... Molecular Pharmaceutics 17 (9), 3553-3566, 2020 | 41 | 2020 |
| Preclinical Evaluation of 225Ac-Labeled Single-Domain Antibody for the Treatment of HER2pos Cancer M Rodak, Y Dekempeneer, M Wojewódzka, V Caveliers, P Covens, ... Molecular Cancer Therapeutics 21 (12), 1835-1845, 2022 | 11 | 2022 |
| Targeted α-Therapy Using 225Ac Radiolabeled Single-Domain Antibodies Induces Antigen-Specific Immune Responses and Instills Immunomodulation Both Systemically and at the Tumor … T Ertveldt, A Krasniqi, H Ceuppens, J Puttemans, Y Dekempeneer, ... Journal of Nuclear Medicine 64 (5), 751-758, 2023 | 5 | 2023 |
| The therapeutic potential of anti-HER2 2Rs15d nanobody labeled with 225Ac–an in vitro and in vivo evaluation☆☆☆ M Pruszynski, M D’huyvetter, M Rodak, Y Dekempeneer, E Cedrowska, ... Journal of Medical Imaging and Radiation Sciences 50 (4), S73-S74, 2019 | 5 | 2019 |
| Preclinical evaluation of astatinated nanobodies for targeted alpha therapy YD Dekempeneer, M D'Huyvetter, E Aneheim, C Xavier, T Lahoutte, ... European Journal of Nuclear Medicine and Molecular Imaging 44, S133-S134, 2017 | 2 | 2017 |
| Preclinical Evaluation of a Radiotheranostic Single-Domain Antibody Against Fibroblast Activation Protein α Y Dekempeneer, S Massa, F Santens, L Navarro, M Berdal, MM Lucero, ... Journal of Nuclear Medicine 64 (12), 1941-1948, 2023 | 1 | 2023 |
| Preclinical characterization of [18F] FB-labeled single-domain antibodies for PET imaging of FAP-a or Folate-a overexpression in cancer H Dierick, L Navarro, H Ceuppens, Y De Vlaeminck, T Ertveldt, ... NUCLEAR MEDICINE AND BIOLOGY 126, S226-S227, 2023 | | 2023 |
| Preclinical characterization of [18F] FB-labeled single-domain antibodies for PET imaging of FAP-α or Folate-α overexpression in cancer H Dierick, L Navarro, H Ceuppens, Y De Vlaeminck, T Ertveldt, ... Nuclear Medicine and Biology 126, 108697, 2023 | | 2023 |
| Development of [68Ga] Ga-DOTA-4AH29, a radiolabeled single-domain antibody for PET imaging of FAP-α expression in cancer M Berdal, M Lucero, AR Antunes, F Santens, Y Dekempeneer, T Lahoutte, ... Nuclear Medicine and Biology 126, 108454, 2023 | | 2023 |
| Accepted poster session at ImmunoRad 2023: Targeted alpha therapy using Actinium-225 radiolabeled single domain antibodies induces antigen-specific immune responses and … T Ertveldt, A Krasniqi, H Ceuppens, J Puttemans, Y Dekempeneer, ... ImmunoRad 2023: The International Conference on Immunotherapy Radiotherapy …, 2023 | | 2023 |
| Targeted alpha therapy using Actinium-225 radiolabeled single domain antibodies induces antigen-specific immune responses and instills immunomodulation both systemically and at … T Ertveldt, K Breckpot, N Devoogdt, J Puttemans, K De Veirman, ... | | 2022 |
| Optimizing the therapeutic index of sdAb-based radiopharmaceuticals using a pretargeting strategy S Poty, L Ordas, Y Dekempeneer, AA Parach, L Navarro, F Santens, ... EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING 49 (SUPPL 1 …, 2022 | | 2022 |
| Preclinical endoradiotherapy using a radiolabeled single-domain antibody targeting Fibroblast Activation Protein M D'Huyvetter, S Massa, Y Dekempeneer, F Santens, L Navarro, ... Journal of Nuclear Medicine 63 (supplement 2), 2457-2457, 2022 | | 2022 |
| 225Ac labeled anti-HER2 2Rs15d sdAb as a potential therapeutic for targeted alpha therapy–an in vitro and in vivo evaluation M Rodak, Y Dekempeneer, M Wojewodzka, T Lahoutte, F Bruchertseifer, ... Nuclear Medicine and Biology 96, S33, 2021 | | 2021 |
| Investigating immune activation upon beta targeted radionuclide therapy using anti-CD20 single domain antibody fragments in melanoma T Ertveldt, Y Dekempeneer, L De Beck, C Goyvaerts, Q Lecocq, ... BACR Annual Meeting 2020: Cancer metastasis: From bedside to bench, 2020 | | 2020 |
| Targeted alpha therapy with single-domain antibody fragments, a novel cancer treatment Y Dekempeneer | | 2020 |
| Targeted radionuclide therapy using anti-CD20 sdAbs: assessment of immune-activation post treatment with beta-emitting radionuclides T Ertveldt, A Krasniqi, M Keyaerts, C Goyvaerts, Q Lecocq, ... ORC-day 2019, 2019 | | 2019 |
